Helping you detect, treat and manage arthritis

Let BC PharmaCare hear “Your Voice” on denosumab (Prolia®) for osteoporosis in men

Cartoon man with arrowBC PharmaCare is looking for your input on denosumab (Prolia®) for the treatment of osteoporosis in men

Denosumab (Prolia®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide direct feedback about denosumab for the treatment of osteoporosis in men.

You can give input if you are a male B.C. resident living with osteoporosis, a caregiver to someone with osteoporosis, or if your group represents people who live with osteoporosis.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.

It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:

  • To view the information sheet for denosumab: click here
  • For the Patient Questionnaire: click here
  • For the Caregiver Questionnaire: click here
  • For the Patient Group Questionnaire: click here Patient groups are required to register their name with the Ministry of Health before making their submission.)

The submission deadline is 11:59pm on August 19, 2015. Patients and caregivers may give their input directly through the links above.

Alternatively, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf. Please provide your input to us by Monday, August 17 so that we may submit the questionnaire in time for the deadline.

About denosumab (Prolia®)

Denosumab has been approved for use by Health Canada for women with postmenopausal osteoporosis with clinical or radiographically-documented fracture due to osteoporosis. This medication is an anti-resorptive therapy that inhibits the development and activation of osteoclasts (the cells that eat away bone). It is administered by an injection under the skin, twice yearly.

About osteoporosis

Osteoporosis is a disease characterized by low bone mass and deterioration of bone quality. This results in bones becoming thin and weak, which increases the risk of fracture, as they are easy to break. Bone loss occurs without any symptoms. An estimated two million Canadians live with osteoporosis. One in four women, including a third of women aged 60-70 years and two thirds of women aged 80 years and older, will be diagnosed with osteoporosis. While it is often considered a “woman’s disease”, one in eight men over the age of 50 have osteoporosis.